主持在研项目：

国家自然科学基金面上项目，82370041，蒿花粉组分Art v1-6损伤气道上皮屏障、促发过敏性哮喘的机制研究，49万，2024-2027年，主持

中国医学科学院临床与转化医学研究基金，2023-I2M-C&T-B-010，变应原免疫治疗方案改良：协和制剂冲击方案的探索与推广，50万，2024-2025，主持

中央高水平医院临床科研专项，2022-PUMCH-B-088，变应原院内制剂疫苗研发及免疫治疗的生物标志物研究，280万，2022-2024年，首席专家

国家自然科学基金面上项目，82070033，蒿属花粉过敏性哮喘集群免疫治疗的生物标志物及作用机制研究，55万，2021-2024年，主持

国家自然科学基金面上项目，82370041，蒿花粉组分Art v1-6损伤气道上皮屏障、促发过敏性哮喘的机制研究，49万，主持

国家自然科学基金面上项目，82070033，蒿属花粉过敏性哮喘集群免疫治疗的生物标志物及作用机制研究，55万，主持

中央高水平医院临床科研专项，2022-PUMCH-B-088，变应原院内制剂疫苗研发及免疫治疗的生物标志物研究，280万，首席专家

北京自然科学基金面上项目资助，7212074，雷暴哮喘的风险预测及发病机制研究，20 万，主持

北京自然科学基金-海淀原始创新联合基金，L2020026，联合铝盐佐剂对蒿属花粉变应原免疫治疗的影响，28万，主持

中国医学科学院临床与转化医学研究基金，2020-I2M-C&T-B-007，“协和变应原制剂”新型免疫治疗方法的临床验证与推广，40万，主持

北京自然科学基金面上项目，7172179，中国蜂毒过敏人群致敏蛋白组份分析和蜂毒变应原诊断试剂研发，20万元，主持

北京协和医学院本科生教学改革项目，2017zlgc0118，变态反应学教学中微课程的应用及试题库建设，10 万，主持

北京协和医学院小规模特色教学项目， 2015zlgc0726，青年教师培养项目资助，10 万，主持

近5年发表SCI文章列表：

Ø  Li L, Wang Z, CuiL, Xu Y, Lee H, Guan K*. The efficacy of a novel smart watch on medicineadherence and symptom control of allergic rhinitis patients: Pilot study. WorldAllergy Organ J. 2023 Jan 7;16(1):100739. doi: 10.1016/j.waojou.2022.100739.PMID: 36694622; PMCID: PMC9840975. (2021-IF 5.516) 

Ø  Li L, Zhang H, WangX, Wang Z, Cui L, Xu Y, Guan K*. Upregulated antimicrobial immune responsemediated by neutrophils in the development from allergic rhinitis to asthma.Front Immunol. 2022 Dec 8;13:1026121. doi: 10.3389/fimmu.2022.1026121. PMID:36569909; PMCID: PMC9771683. (2021-IF 8.786)

Ø  Li Lisha, ChangChristopher, Guan Kai*, Birch Pollen Allergens, Current Protein & PeptideScience 2022; 23(11):731-743. https://dx.doi.org/10.2174/1389203723666220815095725. (2021-IF 3.118)

Ø  Zhang P#, Bian S#,Wang X#, Chen Z, Yang L*, Xiao F*, Guan K*. A real-world retrospective study ofsafety, efficacy, compliance and cost of combination treatment with rush immunotherapyplus one dose of pretreatment anti-IgE in Chinese children with respiratory allergies.Front Immunol. 2022 Oct 4;13:1024319. doi: 10.3389/fimmu.2022.1024319. PMID:36268011; PMCID: PMC9577550. (2021-IF 8.786)

Ø  Guan K#, Zhu W#, ShaL*, Liu C, Zhao J, Yin J*, Chen Y. Prevalence of Sensitization to Aeroallergensin Greater Beijing Region Children With Respiratory Allergy. Front Pediatr.2022 May 19;10:848357. doi: 10.3389/fped.2022.848357. PMID: 35664864; PMCID:PMC9161292. (2021-IF 3.569)

Ø  Bian S, Li L, WangZ, Cui L, Xu Y, Guan K*, Zhao B*. Allergic Reactions After the Administration ofCOVID-19 Vaccines. Front Public Health. 2022 May 17;10:878081. doi: 10.3389/fpubh.2022.878081.PMID: 35655467; PMCID: PMC9152252. (2020-IF 6.461)

Ø  Xu Y, Guan K*. Real-lifedata on inactivated COVID-19 vaccination in patients with subcutaneous allergenimmunotherapy. Clin Transl Allergy. 2022 Jan 20;12(1):e12115. doi: 10.1002/clt2.12115. (2020-IF 5.657)

Ø  Li JD#, Gu JQ#, XuYY, Cui L, Li LS, Wang ZX, Yin J*, Guan K*. Serum IgE profiles in Chinese pollinosispatients with grass pollen sensitisation. World Allergy Organ J. 2022 Jan11;15(1):100624. doi: 10.1016/j.waojou.2021.100624. (2021-IF 5.516) 

Ø  Li JD, Cui L, XuYY, Guan K*. A Case of Anaphylaxis Caused by Major Royal Jelly Protein 3 of RoyalJelly and Its Cross-Reactivity with Honeycomb. J Asthma Allergy. 2021;14:1555-1557.https://doi.org/10.2147/JAA.S346045. (2020-IF 4.258)

Ø  Xu Y, Guan K*, ShaL, Zhang J, Niu Y, Yin J, Wang L. Sensitization Profiles of Timothy Grass Pollenin Northern China. J Asthma Allergy. 2021;14:1431-1439.https://doi.org/10.2147/JAA.S334183.(2020-IF 4.258)

Ø  Bian S#, Zhang P#,Li L, Wang Z, Cui L, Xu Y, Guan K*, Zhao B*, Chen Z*. Anaphylaxis Associated WithAllergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World StudyBased on the US Food and Drug Administration Adverse Event Reporting System.Front Pharmacol. 2021 Oct 22;12:767999. doi: 10.3389/fphar.2021.767999. PMID:34744748; PMCID: PMC8569862. (2020-IF 5.810)

Ø  Bian S, Li L, WangZ, Cui L, Xu Y, Guan K*, Zhao B*, Wang L, Yin J. Neuropsychiatric side reactions of leukotrienereceptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysisof the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).World Allergy Organ J. 2021 Oct 1;14(10):100594. doi: 10.1016/j.waojou.2021.100594.PMID: 34659626; PMCID: PMC8498094. (2020-IF 4.084)

Ø  Zhu W, Liu C, Sha L*, Guan K*, Li S, Shao M,Zhao J, Chen Y. Atypical asthma in children who present with isolated chest tightness:risk factors and clinical features. J Asthma. 2021 Sep 24:1-9. doi: 10.1080/02770903.2021.1980583.Epub ahead of print. PMID: 34559035. (2020-IF 2.515)

Ø  Li L, Wang Z, CuiL, Xu Y, Guan K*, Zhao B*. Anaphylacticrisk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.Clin Transl Allergy. 2021;e12038. https://doi.org/10.1002/clt2.12038. (2020-IF 5.871)

Ø  Lisha Li, Yonglin Liu, Qiang Wang,Zixi Wang, Le Cui, Yingyang Xu, Kai Guan. Levels of nasal exhaled hydrogen sulfidein the general population and allergic rhinitis patients. J Clin Lab Anal. 2021Mar;35(3):e23678. doi: 10.1002/jcla.23678. Epub 2020 Dec 7. (2020-IF 2.352)

Ø  Xu YY, Xue T, Li HR, Guan K*.Retrospective analysis of epidemic thunderstorm asthma in children in Yulin, northwestChina [published online ahead of print, 2020 May 26]. Pediatr Res. 2021 Mar;89(4):958-961.doi: 10.1038/s41390-020-0980-9. Epub 2020 May 26. (2020-IF 3.756)

Ø  Li-Sha Li, Hao Zhang, Meng Wang, Xiu-JieWang, Kai Guan*. Early Transcriptomic Profiling Variation Caused by ClusterAllergen Immunotherapy. Chin Med J (Engl). 2020 Jun 5;133(11):1366-1368. doi: 10.1097/CM9.0000000000000829.(2019-IF 1.585)

Ø  Xu YY, Li JD, Guan K*. Occupationalallergic rhinoconjunctivitis to Tachypleus amoebocyte lysate: a case report. ChinMed J 2020;133(6):743–744. doi: 10.1097/CM9.0000000000000689. (2019-IF 1.585)

Ø  Lisha Li, Kai Guan*, Song GuoZheng*. Biochemical Characteristics and Allergenic Activity of Common Fungus Allergens.Curr Protein Pept Sci. 2020;21(2):170-185. doi: 10.2174/1389203720666190712121243. (2019-IF 2.52)

Ø  Le Cui#, Ying-Yang Xu#, Xiu-Jie Wang,Kai Guan*. Stinging Insect Allergens. Curr Protein Pept Sci. 2020;21(2):142-152.doi: 10.2174/1389203720666191120130209. (2019-IF2.52)

Ø Kai Guan#,Bin Liu#, Meng Wang#, Zhi Li, Christopher Chang, Le Cui, Rui-Qi Wang, Li-PingWen, Patrick S.C. LEUNG*, Ji-Fu Wei*, Jin-Lv Sun*. Principles of allergen immunotherapyand its clinical application in China: Contrasts and Comparisons with the USA. ClinRev Allergy Immunol. 2019 Aug;57(1):128-143. doi: 10.1007/s12016-019-08751-y. (2018-IF 7.328)

Ø  Yan-jun Zhou#, Li-Sha Li#, Jin-LuSun*, Kai Guan*, Ji-Fu Wei*. 1H NMR-based metabolomic study of metabolicprofiling for pollinosis. World Allergy Organ J. 2019 Jan 26;12(1):100005. doi:10.1016/j.waojou.2018.11.005. eCollection 2019. (2018-IF 3.684)

Ø  Xu Y-Y, Li L, Xuan L, Guan K*. Patch test diagnosisof non-immediate cutaneous reaction to myrrh following oral intake of a traditionalChinese medicine decoction. Contact Dermatitis. 2019 Feb;80(2):135-136. doi:10.1111/cod.13144. Epub 2018 Oct 29. (2018-IF 5.504)

Ø  Li L, Wang R, Cui L, Guan K*.Efficacy of Montelukast as Prophylactic Treatment for Seasonal Allergic Rhinitis.Ear, Nose & Throat Journal. 2018;97(7):2-6. doi:10.1177/014556131809700713.(2017-IF 1.010)